Cagrilintide
Also known as: AM833, Long-Acting Amylin Analog, CagriSema Component
Studied in published research — not a medical recommendation. Primary protocol (Phase 2/3 Titration Protocol): 0.25 mg to 2.4 mg (escalating every 4 weeks), Once weekly.
Once weekly
Research-reported range; the linked study used a different dose or units. Often researched alongside Semaglutide or Tirzepatide at 0.25mg–1.0mg/week to break weight-loss plateaus
Subcutaneous injection
Human clinical trials or FDA-approved formulation exists
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 20 doses in the vial at the low end (2 doses at the high end).
Save Cagrilintide to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
Cagrilintide supplier & $/mg comparison.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a GLP-1 Agonist?
A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Cagrilintide is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
Cagrilintide (AM833) is a long-acting, lipidated amylin analog developed by Novo Nordisk. Unlike GLP-1 receptor agonists that act via incretin pathways, Cagrilintide targets calcitonin and amylin receptors (CTR/AMYR) in the hindbrain (area postrema) to induce non-GLP-1 satiety and slow gastric emptying. In Phase 3 REDEFINE trials, it is combined with Semaglutide as CagriSema.
Mechanisms of Action
- Dual agonist of amylin receptors (AMYR1-3) and calcitonin receptors (CTR)
- Acts centrally on the area postrema and nucleus tractus solitarius to enhance meal-induced satiety
- Synergistic weight reduction when stacked with GLP-1 or GIP/GLP-1 agonists without overlapping receptor desensitization
- Half-life of ~7–8 days via C20 fatty diacid acylation (albumin binding)
Research Protocols
Metabolic, Hepatic & Incretin Safety Biomarker Panel (Cagrilintide)
Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.
HbA1c & Fasting Insulin (HOMA-IR)
Day 0 + Wk 6–8Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.
Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.
ALT, AST & GGT Liver Enzymes
Day 0 + Wk 6–8Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.
Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.
ApoB, Triglycerides & Advanced Lipid Panel
Day 0 + Wk 6–8Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.
Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.
Serum Lipase, Amylase & eGFR / Cystatin C
Day 0 + Wk 6–8Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.
Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Currently in Phase 3 trials — not yet FDA approved
- •Requires pH-appropriate reconstitution (check batch salt form before mixing in same syringe with GLP-1s)
- •GI side effects (nausea, early fullness) common during titration
Where to get Cagrilintide, baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Where to buy Cagrilintide: best verified price
Prices checked Nov 11, 2026 · sorted by $/mg · RUO
- 1. Ascension Peptides — $5.00/mg (10mg vial, sold as “C-10”, $50.00)
- 2. Ameano Peptides — $8.80/mg (10mg vial, $88.00)
- 3. Direct Peptides — $10.90/mg (10mg vial, $109.00)
Where is the cheapest place to buy Cagrilintide?
As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $5.00/mg (10mg vial, sold as “C-10”, $50.00 after the 50% new-customer partner-link discount). We compared 10 US suppliers with live, checked prices.
How much does Cagrilintide cost per mg?
Verified US domestic prices currently range from $5.00/mg to $34.00/mg depending on supplier and vial size. Larger vials usually lower the $/mg.
How are these prices verified?
Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.
Is Cagrilintide approved for human use?
Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.
All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More metabolic peptides
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the horm...
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It rep...
Retatrutide
Retatrutide is a triple hormone receptor agonist developed b...
Liraglutide
Liraglutide is an FDA-approved GLP-1 receptor agonist used f...
AOD-9604 (hGH Frag 176-191)
AOD-9604 is a modified fragment of human growth hormone (hGH...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.